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Background: The increasing incidence of Clostridium difficile infections (CDI) in healthcare settings in
Europe since 2003 has affected both patients and healthcare systems. The implementation of effective
CDI surveillance is key to enable monitoring of the occurrence and spread of C. difficile in healthcare and
the timely detection of outbreaks.
Aims: The aim of this review is to provide a summary of key components of effective CDI surveillance
and to provide some practical recommendations. We also summarize the recent and current national CDI
surveillance activities, to illustrate strengths and weaknesses of CDI surveillance in Europe.
Sources: For the definition of key components of CDI surveillance, we consulted the current European
Society of Clinical Microbiology and Infectious Diseases (ESCMID) CDI-related guidance documents and
the European Centre for Disease Prevention and Control (ECDC) protocol for CDI surveillance in acute
care hospitals. To summarize the recent and current national CDI surveillance activities, we discussed
international multicentre CDI surveillance studies performed in 2005e13. In 2017, we also performed a
new survey of existing CDI surveillance systems in 33 European countries.
Content: Key components for CDI surveillance are appropriate case definitions of CDI, standardized CDI
diagnostics, agreement on CDI case origin definition, and the presentation of CDI rates with well-defined
numerators and denominators. Incorporation of microbiological data is required to provide information
on prevailing PCR ribotypes and antimicrobial susceptibility to first-line CDI treatment drugs. In 2017, 20
European countries had a national CDI surveillance system and 21 countries participated in ECDC-
coordinated CDI surveillance. Since 2014, the number of centres with capacity for C. difficile typing has
increased to 35 reference or central laboratories in 26 European countries.
Implications: Incidence rates of CDI, obtained from a standardized CDI surveillance system, can be used
as an important quality indicator of healthcare at hospital as well as country level. M. Krutova, Clin
Microbiol Infect 2018;24:469
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Background manifestations ranging from mild diarrhoea to life-threatening con-Clostridiumdifficile, recently reclassified as Clostridioides difficile, is
a Gram-positive spore-forming ubiquitous bacterium [1]. Toxigenic
strains can cause C. difficile infection (CDI) with diverse clinicalf Medical Microbiology, 2nd
Motol University Hospital, V
M. Krutova).
biology and Infectious Diseases. Puditions. The most important modifiable risk factor for CDI is previous
antibiotic treatment [2]. European data on CDI epidemiology in acute
healthcare derive from a few limited studies with significant differ-
ences in their study design and number of participating healthcare
facilities [3e7]. In response to an increased CDI incidence and spread
of epidemic C. difficile strains belonging to ribotype (RT) 027 in
Europe since 2003 [2e4], the European Society of Clinical Microbi-
ology and Infectious Diseases (ESCMID) published guidance docu-
ments for CDI diagnostics, treatment and infection control [8e10].blished by Elsevier Ltd. All rights reserved.
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Control (ECDC) published a protocol for hospital-based CDI sur-
veillance, to support the implementation of standardized CDI sur-
veillance in Europe [11], in advance of the start of ECDC-
coordinated surveillance of CDI on 1 January 2016.
The objectives of standardized CDI surveillance are to estimate
the incidence and burden of CDI and to acquire information on the
outcome of CDI, including deaths.
The purpose of this review is to provide a summary of key
components of effective CDI surveillance and to provide some
practical suggestions. We also summarize the recent and current
national CDI surveillance activities, to illustrate strengths and
weaknesses of CDI surveillance in Europe.
How to define a CDI case?
The alertness of clinicians to CDI and the availability of labora-
tory diagnostics with appropriate algorithms fundamentally affect
CDI surveillance data. ESCMID currently recommends the system-
atic testing of patients with antibiotic-associated or healthcare-
associated diarrhoea [8]. CDI surveillance is commonly restricted
to hospitalized patients in the acute healthcare setting, even
though several studies have highlighted the importance of CDI in
long-term non-acute care, nursing homes and in the community
[12,13].
According to available guidance, microbiology laboratories
should consider performing tests for CDI on all unformed stools (i.e.
those that take the shape of the container) from healthcare settings
such as acute care hospitals, irrespective of the request from the
physician [5,8]. Solid stool samples should not be tested because of
the absence of diarrhoea and the possibility of detecting asymp-
tomatic C. difficile carriage. Rectal swabs should be used to acquire
laboratory samples from patients with ileus due to reduced peri-
stalsis [8]. Unless there is a strong clinical indication, unformed
stool samples from children <2 years of age should not be tested,
because asymptomatic gastrointestinal carriage is relatively com-
mon in this age group [14,15]. Test-of-cure should be discouraged,
as it is possible to have prolonged carriage of C. difficile, despite the
resolution of diarrhoea [8].
Since 2009, ESCMID has recommended a two-step algorithm for
microbiological diagnosis of CDI [8]. The first step should be a
sensitive test with a high negative predictive value. These should
either be an enzyme immunoassay for the detection of glutamateFig. 1. Decision algorithms for (a) application of Clostridium difficile infection (CDI) case defi
origin of CDI cases.dehydrogenase, or a nucleic acid amplification test for the detection
of C. difficile toxin gene(s). When this screening test is positive, stool
samples should be tested using a sensitive enzyme immunoassay or
a cell cytotoxicity neutralization assay in a second step, to confirm
the presence of free toxins in the stool samples. The use of stand-
alone enzyme immunoassays for toxins should be discouraged
because of their insufficient sensitivity. Stand-alone nucleic acid
amplification tests, which detect the presence of toxin genes, can
overestimate the incidence of CDI, because they do not detect
in vivo toxin production [8,16].
Patients who have had pseudomembranous colitis diagnosed by
lower gastrointestinal endoscopy, or who have characteristic
colonic histopathology, should also be considered to be a CDI case,
without any further requirement for stool sample testing [11,17,18].
However, pseudomembranous colitis is not entirely specific for CDI.
Other pathogens (e.g. cytomegalovirus, Entamoeba histolytica,
Shigella species, Shiga-toxin producing Escherichia coli) and medi-
cation (e.g. cisplatin, cyclosporine A) can cause similar pathology
[19].
A decision algorithm for application of the CDI case definition
using ESCMID-recommended diagnostic algorithm [8] is shown in
Fig. 1a.
CDI case origin
The designation of case origin is determined by the time and
place of the onset of CDI symptoms [2,11,17,18,20], (Fig. 1b).
Cases of ‘healthcare-associated CDI’ (HA CDI) either had an onset
of symptoms in a healthcare facility on day three or later, following
admission to a healthcare facility on day one; or they had onset in
the community within 4 weeks of discharge from a healthcare fa-
cility (the current facility or any other facility).
‘Community-associated CDI’ (CA CDI) cases have had no
discharge from a healthcare facility within the 12 weeks before the
onset of symptoms. In addition, their onset of symptoms either took
place outside healthcare facilities, or took place in a healthcare
facility on the day of admission or on the following day.
If a CDI case has been discharged from a healthcare facility in the
4e12 weeks before the onset of their CDI symptoms, their case
origin is designated as ‘unknown’.
The designation of a CDI case as ‘recurrent’ is independent of the
designation of CDI case origin. Recurrent CDI cases are individuals
who meet the CDI case definition (including return of diarrhoealnition using ESCMID-recommended diagnostic algorithm [8] and (b) designation of the
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treatment, who had new onset of symptoms between 2 and
8 weeks after the onset of symptoms from a previous episode
of CDI.
CDI rates
Presentation of CDI rates as incidence density (cases/10 000
patient-days) or incidence (cases/10 000 admissions) facilitates
comparison of hospitals of different sizes with different surveil-
lance periods. If data on the number of patient-days or number of
admissions are unavailable, suitable alternative denominators
include bed-days (cases/10 000 bed-days) and discharges (cases/
10 000 discharges). Patient-days are calculated by summing the
number of days in which a bed is occupied overnight by patients
hospitalized during the surveillance period. Bed-days are calcu-
lated by multiplying the number of hospital beds by the length of
the surveillance period of that hospital.
All hospitalized patients should be included in the denominator,
including patients on long-term care wards and children aged
2 years. Day patients should be excluded, i.e. hospital patients
who arrive and leave without an overnight stay, such as day cases,
emergency room patients and dialysis patients [11,17,18].
The numerator is the number of hospitalized patients whomeet
the CDI case definitionwho had their onset of CDI symptoms during
the surveillance period, plus the number of CDI cases who were
admitted during the surveillance period with CDI symptom present
at admission. C. difficile-positive children aged2 years should only
be included in the numerator if there is a compelling clinical evi-
dence to diagnose them as a CDI case [11,17,18].
C. difficile isolate characterization for surveillance purposes
Laboratory methods to characterize C. difficile isolates include
PCR ribotyping, detection of the presence of toxin genes or toxin
production and antimicrobial susceptibility testing. Preferably,
typing should be performed at a national reference or central
laboratory.
Polymerase chain reaction (PCR) ribotyping is a molecular
typing method based on variability in a length and number of
copies of intergenic spacer region between genes encoding 16S and
23S ribosomal RNA. Capillary electrophoresis-based PCR ribotyping
has higher discriminatory power, which enables inter-laboratory
data exchange, than conventional agarose-based ribotyping [21].
Four national reference centres in Europe and North America
recently validated a published laboratory protocol for capillary
electrophoresis PCR ribotyping, which has high inter-laboratory
reproducibility [22].
Different C. difficile RTs (strains) may produce different spectra
of toxins (toxin A, toxin B and binary toxin), whereas non-toxigenic
RTs (strains) do not encode the genes for toxin production. Current
protocols for multiplex PCR determine the presence of such
C. difficile virulence factors (e.g. tcdA, tcdB, cdtA and cdtB) [23,24],
although ultimately such data should also be obtainable from
whole genome sequencing.
For the purpose of CDI surveillance, determination of antimi-
crobial susceptibility to metronidazole, vancomycin and moxi-
floxacin is recommended, using European Committee on
Antimicrobial Susceptibility Testing (EUCAST) breakpoints
[11,17,18,25]. Fidaxomicin susceptibility testing should also be
considered, especially in countries that include fidaxomicin in their
CDI treatment recommendations. EUCAST specifies that the MIC
breakpoints for metronidazole and vancomycin are 2 mg/L,
whereas the MIC for moxifloxacin is 4 mg/L. These EUCAST break-
points are based on epidemiological cut-off values that distinguishwild-type isolates from those with reduced susceptibility [25]. No
epidemiological cut-off value has been determined for fidaxomicin
yet, but two European studies suggest a MIC of 0.25 mg/L [26,27].
Agar dilution is recommended for antimicrobial susceptibility
testing [25], particularly if it is performed by a national or central
reference laboratory. Other methods, such as E-test and CLSI agar
incorporation, may not recognize isolates with reduced suscepti-
bility to metronidazole [28].
Incorporation of whole genome sequencing data into CDI sur-
veillance could markedly improve epidemiological investigations
of CDI transmission. Whole genome sequencing data have already
been applied to the analysis of transmission chains of C. difficile
between patients [29e31] and between humans and animals [32].
In addition, genomic data have been used for phylogenetic studies
of epidemic RT017 and RT027 [33,34].
Summary of CDI epidemiology in Europe until 2017
Several European multicentre studies have been performed to
describe CDI epidemiology and to estimate CDI prevalence and
incidence in Europe. In 2000, CDI incidence was estimated to be 1.1
cases per 1000 patient admissions [35]. In 2005, the incidence
density was estimated at 2.5 cases per 10 000 patient-days [3]. In
2008, CDI incidence was estimated at 4.1 cases per 10 000 patient-
days [4]. In 2011e13, a prospective, multicentre, biannual, point
prevalence study of CDI in hospitalized patients with diarrhoea
(EUCLID) estimated an incidence density of 7.0 cases per 10 000
patient-days [5]. The increased CDI incidence rates reported in the
EUCLID studyare probablyassociatedwith the studydesignusing an
optimal testing algorithm. This study also provided strong evidence
that CDI incidence was underestimated in Europe, due to a lack of
awareness for C. difficile testing among physicians [5]. The 2011/12
ECDC point prevalence survey of healthcare-associated infections
and antimicrobial use in European acute care hospitals included
data from >230 000 patients in 33 European countries. The preva-
lence of HACDIwas 3.7%. It estimated that the burden of HACDIwas
123 997 (95% CI 61 018e284 857) cases annually in the European
Union and European Economic Area (EU/EEA) countries [36].
The observed increase in CDI incidence has been concomitant
with changes in the prevailing C. difficile RTs in Europe. The pre-
dominance of RT001 (13%) and RT014/020 (16%) in 2005 and 2008,
respectively [3,4], was displaced by a predominance of RT027 (19%)
by 2012/13 [6]. The emergence of RT027 significantly influenced
CDI surveillance policy worldwide, due to its outbreak potential
and association with notable morbidity and mortality [2,37,38]. For
an overview of results from international multicentre CDI studies in
Europe see Supplementary material (Table S1).
In 2011/12 in Europe, the emergence of reduced susceptibility to
metronidazole and vancomycin and almost 40% resistance to
moxifloxacin was observed among the most prevalent European
RTs of 953 C. difficile isolates tested [26]. A recent study suggests
that variations in the rate of fluoroquinolone prescription may have
been a major factor in the emergence, and later for the control, of
CDI due to fluoroquinolone-resistant C. difficile RTs including RT027
in England [39].
ECDC-coordinated CDI surveillance in the EU/EEA
The ECDC surveillance protocol for European surveillance of CDI
derives from the protocol produced as part of the ECDC-funded
‘European CDI Surveillance Network’ (ECDIS-Net) project [7]. The
protocol specifies three options for surveillance intensity: the
‘minimal option’ that only collects hospital-level aggregate nu-
merators and denominators, the ‘light option’ that also collects
case-based numerators including mortality, and the ‘enhanced
M. Krutova et al. / Clinical Microbiology and Infection 24 (2018) 469e475472option’ that also collects microbiological data on at least the first
ten cases with a unique identifier linking the case-based data [11],
(Table 1).
Fourteen European countries pilot tested the ECDC protocol,
including five countries that did not have ongoing national CDI
surveillance. Thirty-seven hospitals participated and collected data
for 90e92 days between 13 May and 1 November 2013. Thirty-six
hospitals included all wards and one hospital excluded the
neonatal ward. All hospitals used the minimal and light surveil-
lance options; the enhanced option was used by 33 hospitals. Data
were collected for 1152 individuals, of which 1078 also had case-
based data collected using the light or enhanced option. CDI
origin and infection outcome datawere available for 1013 (94%) and
1056 (98%) of these individual, respectively. Of the 317 individuals
for whom enhanced datawere collected, 291 (92%) had a successful
match of their microbiological and epidemiological data. Addi-
tionally, the coordinating laboratory could assign an RT to 268
(92%) of the 291 isolates collected from these individuals [7].
A post-pilot survey regarding the feasibility of the three sur-
veillance options was completed by 26 (79%) of 33 hospitals. They
reported that data collection was ‘not difficult’ for both the light
option (88% hospitals) and the enhanced option (enhanced case-
based data: 88%; microbiological data collection: 92%). The me-
dian times required for the minimal, light and enhanced protocols
were 1.1, 2.0 and 3.0 person-days per 10 000 discharges, respec-
tively [7].
ECDC coordination of CDI surveillance in EU/EEA countries
started on 1 January 2016. During the first year of surveillance,
hospitals in at least 21 (70%) of 30 EU/EEA countries used the
common protocol to acquire comparable CDI surveillance data
[40,41].
As of 6 December 2017, 19 countries had submitted CDI sur-
veillance data to ECDC, for 579 hospital surveillance periods in
2016. Of these hospital surveillance periods, 294 (50.8%) had used
the enhanced surveillance option, 54 (9.3%) had used the light
surveillance option and 231 (39.9%) had used the minimal sur-
veillance option.
The current protocol (version 2.3 from April 2017) requests
microbiological data (enhanced option) from at least five consec-
utive CDI cases, whereas previous protocol versions (versions 2.1
and 2.2) had requested data from ten consecutive isolates [11,17,18].
There is currently no evidence base for the minimum number of
isolates; rather the recommendations were designed to promote
feasibility. Notably, a study in 21 hospitals in the Czech Republic in
2015 identified a difference in the distribution of RTs detected in
the first ten and the second ten consecutive C. difficile isolates
within each hospital [42]. Some countries, such as the Netherlands,
perform comprehensive surveillance of all CDI cases, collectingTable 1
Data collected in the three different Clostridium difficile infection (CDI) surveillance optio
CDI cases
Healthcare-associated, community-associated, unknown association; recurrent cases
CDI testing frequency
Number of stool specimens tested for CDI; number that tested positive for CDI
Hospital denominators
Number of beds, discharges/admissions and patient-bed days
Laboratory algorithm used for CDI diagnosis
CDI case based data
Age, sex, previous hospitalization, CDI case origin, patient outcome including attributa
Microbiological data on C. difficile isolates
Ribotype, presence of toxins/toxin genes, antimicrobial susceptibility testingepidemiological, clinical and microbiological data. This supports
early recognition of outbreaks due to new C. difficile RTs and the
distribution of certain RTs in specific populations [43,44]. As the
ECDC protocol links microbiological data to case data, the hospitals'
collection and reporting of microbiological data from all their cases
will permit faster identification of new strains with increased
morbidity or mortality, thus facilitating initiation of appropriate
control measures.
To support the microbiological aspects of ECDC CDI surveillance,
the Leiden University Medical Centre, the Netherlands, provides
reference typing of C. difficile isolates that are not typeable at na-
tional level in EU/EEA countries, in close collaboration with the
C. difficile reference laboratory in Leeds, UK (open call for tender OJ/
05/11/2015-PROC/2015/029, framework service contract ECDC/
2016/016).
Survey of current CDI surveillance systems in Europe
In August 2017, to update the current knowledge on CDI sur-
veillance in Europe, the ESCMID study group for C. difficile (ESGCD)
conducted a survey by sending a questionnaire to selected subject-
matter experts from EU Member States, Iceland, Norway and
Switzerland. For the UK, representatives from England, Northern
Ireland, Wales and Scotland were contacted separately. The ques-
tionnaire requested information on existing CDI surveillance sys-
tems and availability of reference laboratories for C. difficile in their
country. The survey was completed by 33 out of 34 countries (see
Supplementary material, Table S2).
In this ESGCD survey, 20 of 33 countries reported 24 national
CDI surveillance systems (Fig. 2). This is more than was reported in
a similar survey in 2011, when a CDI surveillance system was in
place in only 14 of the 31 responding European countries [20].
Many of the 24 national surveillance systems report data on
only HA CDI, even though CA CDI and ‘unknown origin’ CDI
constituted 16% of CDIs detected in hospitalized patients during the
pilot survey of European CDI surveillance in 2013 [7]. National
surveillance systems in the Netherlands and Hungary changed in
2011 and 2015, respectively, to provide data on the origin of CDI
cases in hospitalized patients, rather than solely reporting data on
HA CDI.
In 2017, 26 of 33 countries reported the existence of a national
reference or central laboratory for C. difficile in their country,
indicating the availability of support for the enhanced option of the
ECDC CDI surveillance protocol (Fig. 2). The reference laboratories
of 11 countries produced an annual CDI report.
Polymerase chain reaction ribotyping was available for CDI
surveillance in 20 of 31 countries in 2011 and 23 of 32 countries in
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Fig. 2. The presence of Clostridium difficile infection surveillance system and reference or central laboratories for C. difficile in 2017, by country.
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capacity for capillary electrophoresis PCR ribotyping (Slovakia and
Greece). In our 2017 survey, 13 countries reported the availability of
multilocus variable-number tandem-repeats analysis, which is
particularly suitable for outbreak investigation [46e48].
Future perspectives
The incidence of HA CDI is an important quality indicator of
healthcare at hospital as well as country level, reflecting the quality
of both infection prevention and control as well as antimicrobial
stewardship. Results from this ESGCD survey indicate progress
across Europe towards comprehensive monitoring and reporting of
CDI, including provision of detailed microbiological data on circu-
lating C. difficile strains.
There are still options to improve the epidemiological and
microbiological aspects of CDI surveillance. For example, linkage of
CDI surveillance data to antimicrobial and proton pump inhibitor
consumption data at hospital or national level, using existing na-
tional and European databases, may be useful to assess the impact
of antimicrobial use and proton pump inhibitor use on CDI inci-
dence [49]. Additionally, CA CDI is usually only detected if the pa-
tient attends healthcare and is tested for CDI. Monitoring of CA CDI
at national and European level should permit the determination of
CDI incidence in community and identification of prevailing RTs.
Availability of CDI surveillance data in ‘real time’ could be ach-
ieved by implementation of electronic surveillance. Linkage of
hospital administrative information systems to microbiological
information systems will eventually permit automated reporting of
CDI data, enabling rapid identification of outbreaks. Until electronicsurveillance is achievable, frequent reporting of CDI surveillance
data at national and European level should be promoted, in close
collaboration with ECDC.
Published data suggest an increase in CDI incidence in Europe
and rapid changes in the distribution of the most prevalent RTs
[5,6,34,40e42]. This calls for the strengthening of national and Eu-
ropean centres to provide up-to-date diagnostic, prevention and
treatment advice for CDI. Such centres could also providemolecular
typing support for CDI outbreaks in healthcare facilities. Typing (e.g.
PCR ribotyping and eventually whole genome sequencing) data
should optimally be shared within a European network, to enable
early identification of emergent RTs with public health relevance.
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